Target Markets Fever and infectious disease diagnostics in equatorial belt populations represent a large, underserved market ripe for point-of-care rapid tests. This aligns with E25Bio’s strengths in rapid, paper-based diagnostics and field-ready platforms.

Strategic Partnerships Leverage existing collaborations with LabCentral and potential NIH/Gates Foundation networks to access pilot sites, grant-funded programs, and co-development opportunities with academic and hospital systems to accelerate adoption.

Clinical Value Position the product as enabling early treatment decisions and reduced complications, emphasizing cost savings for clinics and healthcare systems through reduced need for centralized labs and faster turnaround times.

Funding Leverage Capitalize on recent VC backing from Khosla Ventures and foundation/tone-aligned funding to pursue strategic co-financing, government procurement programs, and partnerships with larger diagnostics players seeking rapid tests.

Technology Differentiation Highlight paper-based, point-of-care capabilities, minimal cold chain, and digital health integration to differentiate from centralized lab competitors and appeal to distributors and regional health networks seeking scalable, low-resource solutions.